Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18135116 | 0.85 | HPGD (0.52) | HPGDKDM4EALDH1A1ARHDAC1 | |
| SCHEMBL14881202 | 0.84 | KMT2A (0.50) | HPGDKDM4EALDH1A1ARHDAC1 | |
| SCHEMBL14875894 | 0.83 | HDAC1 (0.56) | HPGDKDM4EALDH1A1ARHDAC1 | |
| SCHEMBL14875819 | 0.82 | ALDH1A1 (0.52) | HPGDKDM4EALDH1A1ARHDAC1 | |
| SCHEMBL28823850 | 0.82 | HPGD (0.53) | HPGDKDM4EALDH1A1ARHDAC1 | |
| Hydrochloric Acid SCHEMBL14881098 | 0.81 | GRM4 (0.44) | HPGDKDM4EALDH1A1ARKMT2A | |
| SCHEMBL18135102 | 0.77 | FFAR1 (0.42) | POLBMAPT | |
| SCHEMBL14876043 | 0.75 | HPGD (0.46) | HPGDKDM4EALDH1A1ARHDAC1 | |
| SCHEMBL14885231 | 0.74 | ANO1 (0.51) | HPGDKDM4EALDH1A1HDAC1HSD17B10 | |
| SCHEMBL14882707 | 0.74 | FFAR1 (0.56) | KDM4EALDH1A1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | ALAD, CYP27A1, FAH | HPGD 682/4885KDM4E 3498/4885ALDH1A1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.